Symbols / VKTX Stock $30.00 -3.78% Viking Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
VKTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Brian Lian Ph.D.
Exch · Country NCM · United States
Market Cap 3.48B
Enterprise Value 2.87B
Income -472.34M
Sales —
FCF (ttm) —
Book/sh 5.57
Cash/sh 5.20
Employees 53
Insider 10d —
IPO Apr 28, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.28
PEG —
P/S —
P/B 5.39
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 5.67
Current Ratio 5.72
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -4.15
EPS next Y -4.12
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-29
Earnings (prior) 2026-04-29
ROA -42.54%
ROE -70.04%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 115.89M
Shs Float 113.07M
Insider Own 2.80%
Instit Own 62.83%
Short Float 21.08%
Short Ratio 10.03
Short Interest 23.11M
52W High 43.15
vs 52W High -30.48%
52W Low 22.96
vs 52W Low 30.67%
Beta 0.82
Impl. Vol. 58.40%
Rel Volume 1.06
Avg Volume 2.67M
Volume 2.84M
Target (mean) $92.44
Tgt Median $97.50
Tgt Low $34.00
Tgt High $125.00
# Analysts 18
Recom Strong_buy
Prev Close $31.18
Price $30.00
Change -3.78%
About

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$92.44
Mean price target
2. Current target
$30.00
Latest analyst target
3. DCF / Fair value
$92.44
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$30.00
Low
$34.00
High
$125.00
Mean
$92.44

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-30 main Cantor Fitzgerald Overweight → Overweight $100
2026-03-23 reit HC Wainwright & Co. Buy → Buy $102
2025-11-12 main Canaccord Genuity Buy → Buy $107
2025-10-29 init Canaccord Genuity — → Buy $106
2025-10-24 main JP Morgan Overweight → Overweight $75
2025-10-23 main Morgan Stanley Overweight → Overweight $102
2025-09-29 reit HC Wainwright & Co. Buy → Buy $102
2025-09-22 reit BTIG Buy → Buy $125
2025-08-19 reit HC Wainwright & Co. Buy → Buy $102
2025-07-24 main Raymond James Strong Buy → Strong Buy $122
2025-07-24 main Citigroup Neutral → Neutral $38
2025-06-25 reit HC Wainwright & Co. Buy → Buy $102
2025-04-28 init Cantor Fitzgerald — → Overweight $104
2025-04-28 reit Truist Securities Buy → Buy $75
2025-04-24 main Morgan Stanley Overweight → Overweight $102
2025-04-24 reit HC Wainwright & Co. Buy → Buy $102
2025-04-17 reit HC Wainwright & Co. Buy → Buy $102
2025-04-08 init Goldman Sachs — → Neutral $30
2025-03-26 reit HC Wainwright & Co. Buy → Buy $102
2025-03-11 reit HC Wainwright & Co. Buy → Buy $102
News
RSS: Latest VKTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-10 AUBUCHON NEIL WILLIAM Officer — 4,475 $33.50 $149,912
2026-01-05 ZANTE GREGORY S Chief Financial Officer — 57,661 $32.09 $1,896,969
2026-01-05 LIAN BRIAN Chief Executive Officer — 233,409 $32.29 $7,692,121
2026-01-05 MANCINI MARIANNA Chief Operating Officer — 57,661 $32.29 $1,901,405
2026-01-02 FOEHR MATTHEW W Director — 3,150 $0.00 $0
2026-01-02 FOEHR MATTHEW W Director — 16,000 $35.11 $561,694
2026-01-02 FOEHR MATTHEW W Director — 16,000 $3.33 $53,280
2026-01-02 SINGLETON J MATTHEW Director — 3,150 $0.00 $0
2026-01-02 ZANTE GREGORY S Chief Financial Officer — 73,049 $0.00 $0
2026-01-02 ROWLAND CHARLES A JR Director — 3,150 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
393.34
+160.63%
150.92
+49.68%
100.83
+43.31%
70.36
Research And Development
344.95
+239.38%
101.64
+59.30%
63.81
+17.65%
54.23
Selling General And Administration
48.39
-1.81%
49.28
+33.11%
37.02
+129.64%
16.12
General And Administrative Expense
48.39
-1.81%
49.28
+33.11%
37.02
+129.64%
16.12
Other Gand A
48.39
-1.81%
49.28
+33.11%
37.02
+129.64%
16.12
Total Expenses
393.34
+160.63%
150.92
+49.68%
100.83
+43.31%
70.36
Operating Income
-393.34
-160.63%
-150.92
-49.68%
-100.83
-43.31%
-70.36
Total Operating Income As Reported
-393.34
-160.63%
-150.92
-49.68%
-100.83
-43.31%
-70.36
EBITDA
-392.91
-160.94%
-150.57
-49.77%
-100.53
-43.49%
-70.06
Normalized EBITDA
-392.97
-160.78%
-150.69
-49.89%
-100.53
-43.58%
-70.02
Reconciled Depreciation
0.43
+24.57%
0.35
+18.49%
0.29
+0.34%
0.29
EBIT
-393.34
-160.63%
-150.92
-49.68%
-100.83
-43.31%
-70.36
Total Unusual Items
0.06
-50.89%
0.11
—
-0.04
Total Unusual Items Excluding Goodwill
0.06
-50.89%
0.11
—
-0.04
Net Income
-359.64
-227.05%
-109.96
-28.02%
-85.89
-24.73%
-68.87
Pretax Income
-359.64
-227.05%
-109.96
-28.02%
-85.89
-24.73%
-68.87
Net Non Operating Interest Income Expense
33.65
-17.62%
40.85
+173.55%
14.93
+875.95%
1.53
Net Interest Income
33.65
-17.62%
40.85
+173.55%
14.93
+875.95%
1.53
Interest Income Non Operating
33.70
-17.67%
40.94
+172.57%
15.02
+845.25%
1.59
Interest Income
33.70
-17.67%
40.94
+172.57%
15.02
+845.25%
1.59
Other Income Expense
0.06
-50.89%
0.11
—
-0.04
Gain On Sale Of Security
0.06
-50.89%
0.11
—
-0.04
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-359.64
-227.05%
-109.96
-28.02%
-85.89
-24.73%
-68.87
Net Income From Continuing Operation Net Minority Interest
-359.64
-227.05%
-109.96
-28.02%
-85.89
-24.73%
-68.87
Net Income From Continuing And Discontinued Operation
-359.64
-227.05%
-109.96
-28.02%
-85.89
-24.73%
-68.87
Net Income Continuous Operations
-359.64
-227.05%
-109.96
-28.02%
-85.89
-24.73%
-68.87
Normalized Income
-359.69
-226.77%
-110.08
-28.15%
-85.89
-24.80%
-68.83
Net Income Common Stockholders
-359.64
-227.05%
-109.96
-28.02%
-85.89
-24.73%
-68.87
Diluted EPS
-3.19
-215.84%
-1.01
-10.99%
-0.91
-1.11%
-0.90
Basic EPS
-3.19
-215.84%
-1.01
-10.99%
-0.91
-1.11%
-0.90
Basic Average Shares
112.67
+3.33%
109.04
+15.57%
94.35
+22.79%
76.83
Diluted Average Shares
112.67
+3.33%
109.04
+15.57%
94.35
+22.79%
76.83
Diluted NI Availto Com Stockholders
-359.64
-227.05%
-109.96
-28.02%
-85.89
-24.73%
-68.87
Total Other Finance Cost
0.06
-40.43%
0.09
+6.82%
0.09
+49.15%
0.06
Line Item Trend 2023-12-31 2022-12-31
Total Assets
368.49
+118.65%
168.53
Current Assets
367.23
+119.84%
167.04
Cash Cash Equivalents And Short Term Investments
362.08
+132.87%
155.49
Cash And Cash Equivalents
55.52
+51.55%
36.63
Other Short Term Investments
306.56
+157.93%
118.85
Prepaid Assets
2.62
-67.78%
8.14
Other Current Assets
2.52
-26.06%
3.41
Total Non Current Assets
1.26
-15.04%
1.49
Net PPE
1.13
-20.59%
1.42
Gross PPE
1.13
-20.59%
1.42
Properties
0.00
0.00
Buildings And Improvements
1.13
-20.59%
1.42
Non Current Deferred Assets
0.11
+178.95%
0.04
Non Current Prepaid Assets
0.03
+0.00%
0.03
Total Liabilities Net Minority Interest
20.07
-13.51%
23.21
Current Liabilities
19.14
-12.81%
21.95
Payables And Accrued Expenses
18.81
-13.09%
21.64
Payables
7.51
-11.92%
8.53
Accounts Payable
7.51
-11.92%
8.53
Current Accrued Expenses
11.30
-13.84%
13.11
Current Debt And Capital Lease Obligation
0.32
+6.58%
0.30
Current Capital Lease Obligation
0.32
+6.58%
0.30
Total Non Current Liabilities Net Minority Interest
0.94
-25.71%
1.26
Long Term Debt And Capital Lease Obligation
0.94
-25.71%
1.26
Long Term Capital Lease Obligation
0.94
-25.71%
1.26
Stockholders Equity
348.42
+139.76%
145.32
Common Stock Equity
348.42
+139.76%
145.32
Capital Stock
0.00
+0.00%
0.00
Common Stock
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
Share Issued
102.31
+27.17%
80.45
Ordinary Shares Number
100.11
+27.93%
78.26
Treasury Shares Number
2.19
+0.00%
2.19
Additional Paid In Capital
733.55
+64.74%
445.27
Retained Earnings
-377.94
-29.41%
-292.05
Gains Losses Not Affecting Retained Earnings
-0.39
+64.70%
-1.10
Treasury Stock
6.79
+0.00%
6.79
Other Equity Adjustments
-0.39
+64.70%
-1.10
Total Equity Gross Minority Interest
348.42
+139.76%
145.32
Total Capitalization
348.42
+139.76%
145.32
Working Capital
348.09
+139.91%
145.09
Invested Capital
348.42
+139.76%
145.32
Total Debt
1.26
-19.44%
1.56
Capital Lease Obligations
1.26
-19.44%
1.56
Net Tangible Assets
348.42
+139.76%
145.32
Tangible Book Value
348.42
+139.76%
145.32
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-278.69
-217.45%
-87.79
-19.64%
-73.38
-51.61%
-48.40
Cash Flow From Continuing Operating Activities
-278.69
-217.45%
-87.79
-19.64%
-73.38
-51.61%
-48.40
Net Income From Continuing Operations
-359.64
-227.05%
-109.96
-28.02%
-85.89
-24.73%
-68.87
Depreciation Amortization Depletion
0.43
+24.57%
0.35
+18.49%
0.29
+0.34%
0.29
Depreciation
0.43
+24.57%
0.35
+18.49%
0.29
+0.34%
0.29
Depreciation And Amortization
0.43
+24.57%
0.35
+18.49%
0.29
+0.34%
0.29
Other Non Cash Items
0.07
-50.00%
0.13
+0.76%
0.13
+31.00%
0.10
Stock Based Compensation
40.82
+37.38%
29.71
+77.39%
16.75
+93.13%
8.67
Operating Gains Losses
-0.06
+50.89%
-0.11
—
—
Gain Loss On Investment Securities
-0.06
+50.89%
-0.11
—
—
Change In Working Capital
48.98
+423.16%
9.36
+163.87%
3.55
-65.18%
10.19
Change In Receivables
5.08
+323.35%
1.20
+273.52%
0.32
-47.72%
0.61
Change In Prepaid Assets
-5.20
-1265.70%
0.45
-93.04%
6.41
+304.73%
-3.13
Change In Payables And Accrued Expense
49.61
+510.99%
8.12
+386.49%
-2.83
-121.98%
12.89
Change In Accrued Expense
6.17
+6.05%
5.82
+420.26%
-1.82
-131.26%
5.81
Change In Payable
43.44
+1786.15%
2.30
+326.23%
-1.02
-114.37%
7.08
Change In Account Payable
43.44
+1786.15%
2.30
+326.23%
-1.02
-114.37%
7.08
Change In Other Current Liabilities
-0.51
-25.62%
-0.40
-15.85%
-0.35
-83.60%
-0.19
Investing Cash Flow
341.39
+161.69%
-553.37
-208.99%
-179.09
-427.08%
54.75
Cash Flow From Continuing Investing Activities
341.39
+161.69%
-553.37
-208.99%
-179.09
-427.08%
54.75
Net Investment Purchase And Sale
341.39
+161.69%
-553.37
-208.99%
-179.09
-427.08%
54.75
Purchase Of Investment
-418.04
+62.45%
-1,113.37
-132.77%
-478.30
-293.89%
-121.43
Sale Of Investment
759.42
+35.61%
560.00
+87.16%
299.22
+69.83%
176.18
Financing Cash Flow
76.44
-87.52%
612.46
+125.69%
271.38
+6418.76%
4.16
Cash Flow From Continuing Financing Activities
76.44
-87.52%
612.46
+125.69%
271.38
+6418.76%
4.16
Net Common Stock Issuance
0.00
-100.00%
597.09
+121.34%
269.76
+4057.17%
-6.82
Common Stock Payments
—
0.00
0.00
+100.00%
-6.82
Repurchase Of Capital Stock
—
0.00
0.00
+100.00%
-6.82
Proceeds From Stock Option Exercised
2.49
-76.96%
10.81
+59.77%
6.77
+698.11%
0.85
Net Other Financing Charges
73.95
+1522.73%
4.56
+188.45%
-5.15
-150.85%
10.13
Changes In Cash
139.14
+584.95%
-28.69
-251.70%
18.91
+79.81%
10.52
Effect Of Exchange Rate Changes
-0.01
+94.59%
-0.15
-393.33%
-0.03
+88.37%
-0.26
Beginning Cash Position
26.68
-51.95%
55.52
+51.55%
36.63
+38.91%
26.37
End Cash Position
165.81
+521.57%
26.68
-51.95%
55.52
+51.55%
36.63
Free Cash Flow
-278.69
-217.45%
-87.79
-19.64%
-73.38
-51.61%
-48.40
Amortization Of Securities
-9.28
+46.23%
-17.27
-110.52%
-8.20
-773.95%
1.22
Change In Interest Payable
—
—
—
0.61
Common Stock Issuance
0.00
-100.00%
597.09
+121.34%
269.76
—
Issuance Of Capital Stock
0.00
-100.00%
597.09
+121.34%
269.76
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category